Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simtuzumab in Primary Sclerosing Cholangitis
NCT01672853Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Mar 2013
- Primary completion
- Aug 2016
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 2 trial of simtuzumab in Primary Sclerosing Cholangitis (PSC), sponsored by Gilead Sciences. Started Mar 2013; status: completed.
02
Drugs
simtuzumab
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on NCT01672853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01672853.